Mastodawn

Merck’s $6.7B Terns buy is less about leukemia than life after Keytruda.

When one drug drives nearly half of revenue, M&A becomes a way to buy time before the patent cliff.

Read:
https://biotech.industryexaminer.com/merck-terns-deal-keytruda-patent-cliff-biotech-m-and-a/

#Biotech #Pharma #Merck #Oncology #PatentCliff #BiotechM&A #TechNews #BioTechne

Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda - Biotech Industry Examiner

The target is a leukemia drug developer. The real objective is something larger: time, diversification, and a more believable post-Keytruda growth story.

Biotech Industry Examiner